Investigational drug plus bevacizumab for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced colorectal cancer that has spread and is not removable by surgery.
- Your cancer has not responded to or you could not tolerate your last standard therapy.
- Your cancer is a certain type (mismatch repair proficient or microsatellite stable).
- You are willing to use effective birth control during and 6 months after treatment.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new version of the chemotherapy drug irinotecan (called liposomal irinotecan) combined with bevacizumab, a targeted therapy, for people with colorectal cancer that has spread and has stopped responding to irinotecan. The goal is to see if this combination can control the tumor better.
This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.
This trial tests a combination of two targeted therapies (QL1706 and bevacizumab) plus standard chemotherapy for people with a specific form of metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR. The goal is to see if this triplet works better than standard treatment alone.
This trial tests a new drug (IBI363) combined with either bevacizumab or furuitinib for people with advanced colorectal cancer that has worsened after standard treatments. It aims to find a more effective option for those who have limited alternatives.
This trial is for people with advanced colorectal cancer that has stopped responding to first-line treatment. It tests a combination of chemotherapy, a targeted therapy, and an investigational drug to see if it can help slow the cancer's growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.